Loading asset research
Tenax Therapeutics Inc. Common Stock
TENXNasdaq · USD · StocksQuote as of · Exchange session not verified$1.83
-3.95%
Today
TENX
Loading 1D prices…
Market cap
$68.3M
Volume
4.1M
52w high
$19.4052w low
$1.31Company profile
Tenax Therapeutics Inc. Common Stock
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
CHAPEL HILL, NC, United States
Employees
14
Fiscal year end
1231
CIK
34956
Session & valuation
Open$1.89
Previous close$1.90
Day high$1.91
Day low$1.80
30-day avg. volume6.6M
Outstanding shares37.4M
Diluted EPS-$1.34
Latest annual period
P/E (trailing)-1.36
P/E (forward)-1.22
Price / book0.80
Beta0.82
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ATHEAlterity Therapeutics Limited American Depositary Shares | $68.6M | — | — | -$1.33 | +6.20% | Buy |
| PLRXPliant Therapeutics Inc. Common Stock | $67.8M | $0.00 | — | -$2.43 | +1.33% | Sell |
| CNTBConnect Biopharma Holdings Limited Ordinary Shares | $69M | $64K | -86687.50% | -$1.00 | +2.34% | Buy |
| APLMApollomics Inc. Class A Ordinary Shares | $70.1M | $8.5M | -128.69% | -$52.80 | +0.34% | Unrated |
| PMVPPMV Pharmaceuticals Inc. Common Stock | $70.8M | $0.00 | — | -$1.48 | -2.19% | Buy |